Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.
about
Crizotinib resistance: implications for therapeutic strategiesThe role of the ALK receptor in cancer biologyCrizotinib: from discovery to accelerated development to front-line treatmentTackling ALK in non-small cell lung cancer: the role of novel inhibitorsALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistanceThe Evolution of Therapies in Non-Small Cell Lung CancerTargeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enoughThe Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung CancerOverall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?Identifying therapeutic targets in gastric cancer: the current status and future directionMutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.First-line treatment of advanced ALK-positive non-small-cell lung cancer.Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis.The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.Safety and efficacy of targeted agents monotherapy in advanced NSCLC.Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context.The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions.Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future.Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC.ALK gene alterations in cancer: biological aspects and therapeutic implications.Alectinib for treatment of ALK-positive non-small-cell lung cancer.Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance.Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancerImmunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives.Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.Current and future treatment of anaplastic lymphoma kinase-rearranged cancer.A few pills twice a day keep ALK-positive non-small-cell lung cancer at bay.Genetic Characterization of Brain Metastases in the Era of Targeted Therapy.Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation.ASCEND-5: too little too late?Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.
P2860
Q26738381-3B15E7DA-8EC0-4749-B58F-8019916CEEA8Q26738384-4CAE30D3-3DEF-4084-A567-E15E7608B20EQ26738385-5205DE9B-5963-4B55-8A3B-A579E53AC3C7Q26740329-B75A4190-6303-47B4-A1B6-F1885776FA6CQ26775347-C60BD986-C160-48D0-8D84-A7A04926AD6BQ26786932-04C021BA-6B85-4F9D-8108-AB58E8075C5DQ26799467-BF39A7E8-E2BA-46D1-BB44-29A5B4791D12Q28067196-6E1CB4CB-C530-4E27-80E5-345C16B2CE2FQ33591738-E14E9F7D-5E86-48F4-B30E-DF28E7F58BD0Q36322851-F140E92A-2305-49D3-B1B5-F5B3EE84249BQ36398732-8471BA97-9F51-480D-89DE-9D3739805265Q37051546-88330B37-1898-46E3-95F4-9624F4025E5DQ37566842-BA9FC5D6-13B9-4684-9B49-CA92C2299589Q37592115-5D53A300-AEB0-4AFF-9061-F66D310828FEQ37697125-1C01FA2E-4C20-4295-A0F7-7A24E0098B5BQ38558178-F9F4D078-C86F-478D-908C-494D8F3A42E2Q38630725-43AAE1B2-074C-4485-8D2A-66290031B512Q38631019-32893E3D-B64A-43C0-84C4-F871D36D39EFQ38635259-81A5BB91-FEAA-4ADF-8D58-17144D3C55B7Q38638022-CC3FC979-EC7F-4467-8FCC-146B12C4193CQ38663460-949440B9-B219-4E61-9F90-22ED64FD349DQ38689104-6D3C4BA3-20E0-4455-A9CB-B16C3C3906CDQ38763108-C0139885-FE47-4305-9383-C036B2E346F0Q38767006-16187A79-7A56-4A88-B3E7-70E20892D811Q38805618-323D4FAA-33E7-4C9E-A2A1-F29BE2203D00Q38816270-B27C08DF-C669-433C-80B2-F49C901927B2Q38816700-51E7EF9D-5338-46C5-820F-8F10D5DA46B7Q38828319-27E6E7D0-87DF-45C4-BC4F-E78C72B42C3CQ38829087-43252970-2142-4E73-BFD1-811226D5B703Q39027385-8AE1D7E2-0355-4019-8412-DF1D16DC9B32Q39139953-D9177A33-F844-4593-A1B0-1DBA27057155Q39835396-5796F389-BBD2-42ED-BC16-0746AB9183EDQ41636404-8EA41498-4BE0-4EF1-9F40-C2A3A941F983Q41879369-37ADA1D4-27B7-4D1B-B49C-98AF3E84B0BEQ42012859-D941264D-51DE-4B7E-8875-2AE3F4E3A7A9Q42357373-DDA583D5-41AC-4C77-840A-BF354F1E84E2Q42367836-2C7F3949-99D8-4BCF-8FEB-FA60C2D11904Q42369337-9771C76C-3536-4C86-98E8-DCC4786268D8Q47096142-4B9C2EFA-7544-42D1-81B3-690C7ABDF3DEQ47108604-EC365E1D-8453-48C8-925A-634F3D357402
P2860
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Progression-Free and Overall S ...... tial Crizotinib and Ceritinib.
@ast
Progression-Free and Overall S ...... tial Crizotinib and Ceritinib.
@en
type
label
Progression-Free and Overall S ...... tial Crizotinib and Ceritinib.
@ast
Progression-Free and Overall S ...... tial Crizotinib and Ceritinib.
@en
prefLabel
Progression-Free and Overall S ...... tial Crizotinib and Ceritinib.
@ast
Progression-Free and Overall S ...... tial Crizotinib and Ceritinib.
@en
P2093
P2860
P1476
Progression-Free and Overall S ...... tial Crizotinib and Ceritinib.
@en
P2093
Alice T Shaw
Aziah Ahmad
Benjamin J Solomon
Beow Y Yeap
Chiara Lazzari
Daniel S W Tan
Filippo de Marinis
Gianluca Spitaleri
Jeffrey A Engelman
Justin F Gainor
P2860
P304
P356
10.1158/1078-0432.CCR-14-3009
P407
P577
2015-02-27T00:00:00Z